A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

This study is being done to answer the following question: How tolerable is the new combination of durvalumab with classic chemotherapy (gemcitabine and cisplatin) before surgery for your high-risk liver cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your liver cancer. The usual approach is defined as care most people get for liver cancer.

Are you Eligible? (Inclusion Criteria)

• Age ≥ 18 years Patients must have histologically or cytologically confirmed intrahepatic cholangiocarcinoma (iCCA) that is resectable by imaging evaluation Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension